Compare Aurora Cannabis Inc (ACB) vs Clorox Co (CLX) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

CLX trades at $97.41, up 0.15% on the day, with a neutral technical signal and key support at $96. The company reported Q1 2026 EPS of $1.64, beating expectations, and maintains strong profitability with an 11.18% net margin. Recent news highlights a simplified operating structure and CEO transition, while analyst consensus is a $103.38 price target with a hold-heavy rating distribution.

The outlook is mixed: solid fundamentals and a nearly 5% dividend yield support income investors, but high debt levels and competitive pressures pose risks. Upside depends on execution of new growth initiatives under incoming leadership, with current valuation appearing reasonable relative to peers.